Haematology

Hematology Department Profile

I. Department Overview

The Department of Hematology of the First Affiliated Hospital of Chongqing Medical University was established in 1956 after the Affiliated Hospital of Shanghai First Medical College relocated partially to Chongqing. It is one of the large hematology specialties in China and Southwest China integrating medical care, teaching, and research. It is currently a National Clinical Key Specialty, a Key Specialty of the Chongqing Municipal Education Commission, a National Drug Clinical Trial (GCP) Base, and the Chongqing Hematopoietic Stem Cell Transplantation Base; it is a council-member institution of the Chinese Hematology Disease Specialty Alliance and the lead institution of the Bayu Hematology Disease Specialty Alliance. It ranks among the top in Fudan’s regional specialty reputation rankings, and the specialty has considerable influence in Southwest China.

The department currently has 121 open beds, including 15 Class 100 laminar-flow rooms with advanced facilities. It admits approximately 4000 inpatients annually, mainly patients with hematologic malignancies such as leukemia, MDS, lymphoma, and myeloma. Its comprehensive treatment capability has reached an advanced national and international level. It has strong research capacity, with dozens of ongoing national- and municipal-level research projects. Its main research directions include basic and clinical research on hematopoietic stem cell transplantation, the molecular pathogenesis of hematologic malignancies, and the diagnosis and treatment of difficult and complex hematologic diseases.

II. Specialty Features

1. Hematopoietic stem cell transplantation: The department has successfully performed related-donor, unrelated-donor, haploidentical, and other allogeneic hematopoietic stem cell transplantations, as well as autologous hematopoietic stem cell transplantation. More than 1000 hematopoietic stem cell transplantations have been completed in total, and more than 100 are currently performed annually. The transplantation volume and post-transplant cure rate are at an advanced national and international level.

Sterile laminar-flow ward

2. Clinical laboratory testing for hematologic diseases: The department offers a full range of tests and meets the requirements of the most advanced hematologic MICM diagnosis, including bone marrow morphology, flow cytometry, cytogenetics, molecular biology, and others.

Hematology and Bone Marrow Laboratory

Chongqing Molecular Testing Center: MICM Diagnostic Platform

3. Hematology subspecialties: These include hematopoietic stem cell transplantation, leukemia and MDS, lymphoma, and multiple myeloma.

4. Medical professional technologies: In addition to the various hematopoietic stem cell transplantation techniques described above, the department routinely performs plasma exchange, therapeutic component apheresis, and high-dose chemotherapy. It also possesses the most advanced international capabilities in precision diagnosis and treatment of hematologic malignancies, the implementation of which requires comprehensive analysis integrating information from molecular testing, second-generation sequencing, bioinformatics, targeted medications, and other sources. The department also masters biological immunotherapy for tumors, represented by CART cell therapy. For patients with newly diagnosed, relapsed, or refractory hematologic malignancies, individualized high-dose chemotherapy combined with targeted therapy and biological therapy greatly improves long-term survival.

III. Talent Structure

The medical team comprises personnel with senior professional titles, accounting for 50% (12 people), while intermediate- and junior-level titles account for 29% (7 people) and 21% (5 people), respectively.

The department is an authorized institution for conferring doctoral and master’s degrees in internal medicine, with 3 doctoral supervisors and 8 master’s supervisors.

Academic leader Director Liu Lin is a renowned hematology expert in Chongqing and an important founder and pioneer of hematopoietic stem cell transplantation technology in the city. He has worked in hematopoietic stem cell transplantation for more than 20 years and has successively chaired multiple sessions of national specialized training courses on hematopoietic stem cell transplantation. He concurrently serves as a national committee member of the 9th through 11th terms of the Hematology Branch of the Chinese Medical Association, a member of the Hematopoietic Stem Cell Transplantation Group of the Hematology Branch of the Chinese Medical Association, a member of the Hematology Physicians Branch of the Chinese Medical Doctor Association, a member of the Hematologic Oncology Professional Committee of the China Anti-Cancer Association, and chair of the Hematologic Oncology Professional Committee of the Chongqing Anti-Cancer Association, among other positions.

Department Director Wang Li is a renowned hematology expert in Chongqing. He has been engaged in the clinical care, teaching, and research of hematologic diseases for 30 years and is the leader of the leukemia and myelodysplastic syndromes group.

He previously conducted postdoctoral research in hematology at the University of Oxford in the United Kingdom and twice studied hematopoietic stem cell transplantation techniques at the Hematology Center of Saint-Louis Hospital of Paris VII University in France. He has led multiple research projects funded by the National Natural Science Foundation of China, the Ministry of Education, and other institutions; he received the Third Prize of the Chongqing Science and Technology Progress Award and has published more than 30 SCI papers. He concurrently serves as a national committee member of the 12th term of the Hematology Branch of the Chinese Medical Association, a member of the Leukemia-Lymphoma Group of the Hematology Branch of the Chinese Medical Association, leader of the Chongqing Regional Center Group of the Chinese Myelodysplastic Syndromes and Myeloproliferative Neoplasms Working Group of the Hematologic Oncology Professional Committee of the China Anti-Cancer Association, deputy chair and secretary of the Hematologic Oncology Professional Committee of the Chongqing Anti-Cancer Association, deputy chair of the Hematology Branch of the Chongqing Medical Association, and deputy chair of the Hematology Physicians Branch of the Chongqing Medical Doctor Association, among other positions.

He serves as a peer-review expert for the Journal of Chongqing Medical University, Journal of the Third Military Medical University, Chongqing Medicine, Laboratory Medicine and Clinic, Chinese Journal of Cell Biology, Oncology letters, and other journals.

IV. Academic Achievements and Honors

Over the past three years, the specialty team has led 16 research projects at various levels and published 96 papers, including 38 SCI papers; the highest impact factor was greater than 20. The team holds 5 invention patents and participated in formulating 6 industry guidelines and consensus statements.

Academic leader Professor Liu Lin has received 1 Third Prize of the Chongqing Science and Technology Progress Award, the May 1 Labour Medal, and other honors. Other honors include 2 Chongqing young and middle-aged high-end medical talents, 1 Chongqing young and middle-aged high-end medical talent studio, and 1 Youth Outstanding Talent Program of the First Affiliated Hospital of Chongqing Medical University, among others.

Nursing team: Awarded the Chongqing Top Ten Outstanding Nursing Collective.